Claire E.F. Miller
· Assistant Professor (Clinical)University of Utah · Hematology & Oncology
Active 2009–2026
About
Dr. Claire E.F. Miller is an Assistant Professor of Pediatrics at the University of Utah, specializing in Pediatric Hematology Oncology. She received her medical degree from the University of New Mexico School of Medicine and completed a Pediatrics residency at Oregon Health & Science University. Her fellowship training in Pediatric Hematology, Oncology, and Bone Marrow Transplant was completed at Children’s Hospital Colorado, where she also received additional training in clinical research through the Masters of Clinical Science program at the University of Colorado Anschutz Medical Campus. Dr. Miller was an Instructor of Pediatrics at Children’s Hospital Colorado, where she continued to care for patients and developed a research program focused on neurocognitive outcomes in children with cancer and blood disorders. Her clinical care involves patients with leukemia, lymphoma, and long-term survivors of all cancers. Her research program examines neurocognitive dysfunction in childhood cancer survivors, including risk factors, consequences, and interventions to prevent decline.
Research topics
- Computer Science
- Medicine
- Data Mining
- Biology
- Embedded system
- Genetics
- Pathology
- Chemistry
- Data science
- Bioinformatics
- World Wide Web
- Computational biology
- Telecommunications
Selected publications
Journal of the American College of Cardiology · 2026-03-27
articleJournal of the American College of Cardiology · 2025-03-29
articleOpen accessJournal of the American Heart Association · 2025-08-23 · 4 citations
articleOpen accessBACKGROUND: Radiation therapy (RT) can cause cardiac implantable electronic device (CIED) malfunction, primarily reset. Given changes in RT and CIED technologies, large observational studies examining malfunction of contemporary CIEDs during modern-day RT are needed to guide clinical practice. METHODS: Electronic medical records of all consecutive patients with CIEDs who underwent RT at a large tertiary cancer center between January 2015 and January 2022 were reviewed. All patients had CIED interrogation before and after completion of RT. Device-related data and RT-specific variables were collected. Statistical analyses were performed at the RT course level. RESULTS: Over a period of 7 years, 677 patients (median age, 74 [interquartile range, 67. 8-79.2] years; 72% men) with CIEDs (498 [66%] pacemakers and 254 [34%] implantable cardioverter-defibrillators) underwent 752 courses of RT (photon, 83.5%; proton, 10.5%; electron, 6%). Only 9 patients (1.3%) underwent CIED relocation before RT. Device malfunction was observed during 8 RT courses (1.1%), primarily soft reset with data loss. All device malfunctions were observed with neutron-producing radiation (proton and photon >10 MV). CIED type (pacemaker or implantable cardioverter-defibrillator), magnetic resonance imaging conditional or nonconditional system, and radiation site (thorax or nonthorax) did not show statistical differences between RT courses with reset versus no reset. No transient signal interference or oversensing due to RT was recognized by the CIED. CONCLUSIONS: CIED malfunction is a rare complication of contemporary RT, occurring primarily with neutron-producing radiation, most of CIED malfunction cases are without serious clinical consequences. Transient signal interference and oversensing during RT does not appear to be a clinical concern in contemporary CIEDs.
Journal of the American College of Cardiology · 2024-04-01
articleEvaluation of Midodrine Utilization in Patients with Cancer and Heart Failure
Cardiovascular Drugs and Therapy · 2024-01-15 · 4 citations
articleRARE CASE OF AMIODARONE INDUCED CUTANEOUS SMALL VESSEL VASCULITIS AND THROMBOCYTOPENIA
Journal of the American College of Cardiology · 2024-04-01 · 1 citations
articleJournal of the American College of Cardiology · 2023-03-01
articleOpen accessJournal of the American College of Cardiology · 2023-03-01
articleCirculation · 2023-11-07
articleBackground: Historically, the reported incidence of Cardiac Implantable Electronic Device (CIED) malfunction during Radiotherapy (RT) is estimated to range from 3% to 20%. However, most of these studies had small sample sizes and may have overestimated the clinical impact of this problem. In this retrospective study, we examined the incidence of device reset and transient signal interference due to RT in a large cohort of patients. In addition, we studied the feasibility of a novel method of monitoring CIEDs during RT: pulse check method (PCM). Methods: From 1/2015 to 4/2023, patients with CIEDs requiring RT at a tertiary cancer center were identified. CIEDs were checked prior to RT. Candidate patients were managed with PCM, which involves programming the lower pacing rate at 75 bpm (slightly faster than lower rate of pacing during reset mode). Pulse checks were performed after each fraction of RT. Patients with heart rate less than 75 bpm had immediate device interrogation to assess for reset. After completion of RT, devices were interrogated and CIED programming returned to original settings. Results: Our study reviewed 720 patients with CIEDs undergoing 837 courses (560 pacemakers and 277 defibrillators) of RT, of which the majority (85%) were managed with PCM. Neutron producing RT (proton and photon with >10MV beam energy) was used in 189 (22.6%) cases, and 9 (1.1%) devices experienced reset. All resets were recoverable and occurred in the setting of neutron-producing radiation, especially proton therapy [OR 12.06 (3.37 - 43.10), p-value 0.0001]. Site of radiation, type of device, and number of RT fractions did not predict reset. No transient signal interference or oversensing events occurred during RT. Conclusions: CIED malfunction is a rare complication of RT, occurring in the setting of neutron producing radiation, with no serious clinical consequence. Transient signal interference and oversensing during RT was not observed to be a clinical concern in contemporary devices. Thus, asynchronous pacing in pacer dependent patients and deactivation of defibrillator tachy-therapy during RT is not necessary. PCM is a practical and cost-effective way to monitor CIEDs during RT.
Circulation · 2022-11-08
articleIntroduction: Natriuretic peptides (NP) are routinely used for the diagnosis of heart failure. Studies have suggested higher levels of NP in patients with cancer, possibly driven by cancer associated inflammation. This study aims to assess the performance characteristics of natriuretic peptides in predicting invasively measured elevated intracardiac filling pressures in patients with cancer. Methods: Patients with cancer who underwent a right heart catheterization (RHC) at a tertiary cancer center from 10/2011 to 10/2021 were identified. Demographic characteristics, NP levels and invasive hemodynamic data were abstracted. Pulmonary capillary wedge pressure (PCWP) > 15 mmHg and mean right atrial pressure (mRAP) > 8 mmHg were defined as abnormal. Results: Of 1240 patients who underwent a RHC, 740 had NTproBNP (41%) or BNP levels (23%) available within a median of 1 day (0-3, and 0-4 days, respectively) from the procedure. Of those, 46% were female, 70% were white, median age was 67 years (IQR: 58-74) and median BMI was 25.2 kg/m 2 (17.4-30.3). High PCWP was present in 58% of patients while an additional 15% had high mRAP with normal PCWP (73%). The area under the curve (AUC) of NTproBNP and BNP in predicting high PCWP was 0.626 (95% CI 0.578-0.675) and 0.681 (0.617-0.744), respectively. The AUC of NTproBNP and BNP in predicting high PCWP or high mRAP was 0.603 (0.549-0.657) and 0.690 (0.621-0.759), respectively. At 125 pg/ml, NTproBNP had a sensitivity of 95%, specificity 6%, positive predictive value (PPV) 57%, and negative predictive value (NPV) 48% for high PCWP and a sensitivity of 95%, specificity 9%, PPV of 74%, and NPV 41% for high PCWP or high mRAP. At 100 pg/ml, BNP had a sensitivity of 89%, specificity 25%, PPV 64%, and NPV 60% for high PCWP, and a sensitivity of 88%, specificity 28%, PPV 77%, and NPV 47% for high PCWP or high mRAP. Conclusions: NP at the standard cutoff levels are very sensitive in predicting elevated intracardiac filling pressures in patients with cancer. However, they can be falsely elevated in >70% of cancer patients with normal filling pressures. These caveats need to be considered when utilizing elevated levels of NP in the assessment of patients with cancer and dyspnea and/or edema.
Recent grants
NIH · $256k · 2019
Frequent coauthors
- 37 shared
Rutger Vos
Naturalis Biodiversity Center
- 36 shared
Trevor J. Wennblom
Osaka University
- 36 shared
Ricardo H. Ramírez-González
Norwich Research Park
- 36 shared
Geert Smant
Wageningen University & Research
- 36 shared
Jan Aerts
- 36 shared
Ben J. Woodcroft
Translational Research Institute
- 36 shared
N. Goto
Osaka University
- 36 shared
George Githinji
Education
M.D.
University of New Mexico School of Medicine
Other
Oregon Health & Science University
Other
Children’s Hospital Colorado
Other
University of Colorado Anschutz Medical Campus
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Claire E.F. Miller
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup